1042917-53-2

Basic information

• Product Name: 4-(4-Boc-Piperazin-1-ylsulfonyl)phenylboronic acid pinacol ester
• Synonyms: 4-(4-Boc-Piperazin-1-ylsulfonyl)phenylboronic acid pinacol ester;tert-butyl 4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]sulfonylpiperazine-1-carboxylate;tert-Butyl4-{[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)benzene]sulfonyl}piperazine-1-carboxylate;4-(4-BOC-PIPERAZIN-1-YLSULFONYL)PHENYLBORONIC ACID;tert-Butyl 4-{[4-(tetramethyl-1,3,2-dioxaborolan-2-yl)benzene]sulfonyl}piperazine-1-carboxylat
• CAS NO: 1042917-53-2
• Molecular Formula: C₂₁H₃₃BN₂O₆S
• Molecular Weight: 470.3878
• Mol File: 1042917-53-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4-(4-Boc-Piperazin-1-ylsulfonyl)phenylboronic acid pinacol ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(4-Boc-Piperazin-1-ylsulfonyl)phenylboronic acid pinacol ester(1042917-53-2)
• EPA Substance Registry System: 4-(4-Boc-Piperazin-1-ylsulfonyl)phenylboronic acid pinacol ester(1042917-53-2)

Safety Data

• Hazardous Substances Data: 1042917-53-2(Hazardous Substances Data)

Upstream product

• 98-58-8 4-bromobenzenesulfonyl chloride 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 1432451-01-8 NEU-624 
• 1432450-61-7 N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(4-(piperazin-1-ylsulfonyl)phenyl)quinazolin-4-amine 

Relevant articles and documents

MERTK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Medicinal chemistry optimization of antiplasmodial imidazopyridazine hits from high throughput screening of a softfocus kinase library: Part 2

On the basis of our recent results on a novel series of imidazopyridazine-based antimalarials, we focused on identifying compounds with improved aqueous solubility and hERG profile while maintaining metabolic stability and in vitro potency. Toward this objective, 41 compounds were synthesized and evaluated for antiplasmodial activity against NF54 (sensitive) and K1 (multidrug resistant) strains of the malaria parasite Plasmodium falciparum and evaluated for both aqueous solubility and metabolic stability. Selected compounds were tested for in vitro hERG activity and in vivo efficacy in the P. berghei mouse model. Several compounds were identified with significantly improved aqueous solubility, good metabolic stability, and a clean hERG profile relative to a previous frontrunner lead compound. A sulfoxide-based imidazopyridazine analog 45, arising from a prodrug-like strategy, was completely curative in the Plasmodium berghei mouse model at 4 × 50 mg/kg po.

PURINE DERIVATIVES

Purine derivatives of Formula (I), wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as JAK3 kinase inhibitors.